# Cytokine-induced Killer Study for Patients With Stage II Melanoma

> **NCT02498756** · PHASE2 · NOT_YET_RECRUITING · sponsor: **The First People's Hospital of Changzhou** · enrollment: 300 (estimated)

## Conditions studied

- Melanoma

## Interventions

- **BIOLOGICAL:** Cytokine-induced killer cells
- **DRUG:** Ipilimumab

## Key facts

- **NCT ID:** NCT02498756
- **Lead sponsor:** The First People's Hospital of Changzhou
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** NOT_YET_RECRUITING
- **Start date:** 2015-08
- **Primary completion:** 2038-08
- **Final completion:** 2040-08
- **Target enrollment:** 300 (ESTIMATED)
- **Last updated:** 2015-07-15


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02498756

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02498756, "Cytokine-induced Killer Study for Patients With Stage II Melanoma". Retrieved via AI Analytics 2026-05-25 from https://api.ai-analytics.org/clinical/NCT02498756. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*